Is warfarin associated with heavy menstrual bleeding in women of reproductive age?

Yes, warfarin is strongly associated with heavy menstrual bleeding in women of reproductive age.

Warfarin causes heavy menstrual bleeding (HMB) in 22% to 71% of menstruating women, representing a substantial and clinically significant risk that requires proactive screening and management 1.

Magnitude of the Problem

The association between warfarin and HMB is well-established and clinically important:

• Vitamin K antagonists (including warfarin) cause HMB in 22-71% of women 1
• In adolescents specifically, the rate is 19-30% 1
• The FDA drug label explicitly lists bleeding from the genitourinary tract as a contraindication when active bleeding is present 2
• One-quarter of reproductive-aged women on oral anticoagulants (including warfarin) experience HMB that significantly impacts quality of life 3

Clinical Impact on Morbidity and Quality of Life

The bleeding is not merely a nuisance—it has real consequences:

• HMB from anticoagulation leads to iron deficiency and anemia, yet only 9.2% of women starting anticoagulation receive ferritin screening 4
• Among those screened, 36.6% have ferritin ≤50 ng/mL and 25.8% have ferritin ≤30 ng/mL 4
• The bleeding significantly impairs quality of life, as measured by validated questionnaires 3
• HMB may lead to interruptions in anticoagulation, which paradoxically increases the risk of recurrent VTE 5

Comparison to Other Anticoagulants

While warfarin clearly causes HMB, direct oral anticoagulants (DOACs) have varying profiles:

• Rivaroxaban appears to have the highest bleeding risk, with 41% experiencing HMB 5 and a 34% increased risk of surgical intervention compared to warfarin 6
• Apixaban has a lower HMB profile than rivaroxaban, with mean bleeding scores 54% lower 7
• The rate of anticoagulation-related reproductive tract bleeding ranges from 20-60% across all anticoagulants 1

Critical Management Considerations

The FDA label explicitly contraindicates warfarin in the presence of active genitourinary bleeding 2. However, for women requiring chronic anticoagulation:

1. Screen proactively for HMB before it becomes severe—don't wait for the patient to report it
2. Check ferritin levels within 90 days of starting anticoagulation (currently done in <10% of cases) 4
3. Consider oral progesterone (norethisterone 5mg three times daily) as first-line treatment, which significantly reduces bleeding scores (from mean 162.8 to 105.5) 8
4. Refer to gynecology early when HMB develops—22-30% of adolescents on warfarin require gynecologic referral 9
5. Never interrupt anticoagulation for HMB in patients with recent VTE (≤4 weeks), as this increases thrombotic risk 10

Common Pitfalls

• Failing to screen: Most women are not asked about menstrual bleeding patterns when starting anticoagulation
• Underestimating severity: Women may normalize heavy bleeding and not report it spontaneously
• Stopping anticoagulation: This increases VTE recurrence risk; HMB predisposes to recurrent VTE with an odds ratio of 5.3 5
• Not checking iron stores: Iron deficiency without anemia is common and easily missed without ferritin testing 4

Bottom Line for Clinical Practice

Any woman of reproductive age starting warfarin should be counseled about the 22-71% risk of HMB, have baseline ferritin checked, and be given anticipatory guidance about treatment options 1, 4. The bleeding is real, common, and has significant impact on anemia and quality of life. Proactive interdisciplinary management involving hematology and gynecology is essential 1.